Lipid peroxidation (LP) has recently been suggested to trigger the atherosclerotic process as well as to worsen the progression of renal disease. Autoantibodies against oxidized low-density lipoproteins (Ox-LDLAb) were considered to provide a sensitive marker to detect LDL oxidation in vivo. To date few studies have been reported on Ox-LDLAb levels in patients with different degrees of renal failure. The aim of this study was to evaluate the influences of renal function, dietary manipulation, and lipids on Ox-LDLAb concentrations in uremic patients either on conservative or replacement therapy. Seventy-one patients (42 males, 29 females) aged 60 ± 19 years with chronic renal failure (CRF) of different etiology and degree were divided into four groups according to serum creatinine levels [sCr(mg/dl)] and diet: CRF I ≧1.5–3.0, CRF II > 3.0–5.5, and CRF III > 5.5 were all patients on a conventional low-protein diet, while a fourth group included patients on a vegetarian diet supplemented with keto analogues and amino acids (CRF SD >3.0). A further group was represented by patients on dialysis therapy. All patients were examined for Ox-LDLAb, triglycerides (TG), total cholesterol, HDL and LDL cholesterol, and apolipoproteins Apo A1, Apo B, and Lp(a). The results were compared with those of 20 controls (9 males and 11 females) aged 52 ± 11 years with sCr <1.5 mg/dl. Ox-LDLAb increased, although not significantly, with TG and Lp(a) from the early stages of CRF along with the deterioration of renal function. However, TG and Lp(a) levels were significantly higher in all groups of patients except those on vegetarian diet (CRF SD). This group also showed the lowest Ox-LDLAb levels. No relationship was observed between lipids or apolipoproteins and Ox-LDLAb. Hyperlipidemic patients did not show higher Ox-LDLAb levels than normolipidemics. Our results show a progressive increase of LP as the renal function declines, which may account for the increased risk of cardiovascular disease reported in uremia. Dialysis does not correct significantly the oxidative state observed in patients with end-stage renal disease. Vegan diet, by reducing LP, TG, and Lp(a), is supposed to decrease the risk of cardiovascular disease and worth being reconsidered as an alternative effective therapeutic tool in patients with advanced CRF.

Keywords:
Oxidized low-density lipoproteins, Lipid peroxidation, Lp(a), Chronic renal failure, Vegan diet
1.
Foley RN, Parfrey PS, Sarnak MJ: Cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(suppl 3)–:112–119.
2.
Chan MK, Varghese Z, Moorhead JF: Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int 1981;19:625–637.
3.
Jialal I, Devaraj S: Low density lipoprotein oxidation, antioxidants, and atherosclerosis: A clinical biochemistry perspective. Clin Chem 1996;42:498–506.
4.
Ross R: The pathogenesis of atherosclerosis. Nature 1993;362:801–809.
5.
Moorhead JF, El Nahas M, Chan MK, et al: Lipid nephrotoxicity in chronic progressive glomerular and tubular interstitial disease. Lancet 1982;ii:1309–1311.
6.
Magil AB, Frohlic JJ, Innis SM, et al: Oxidized low-density lipoprotein in experimental focal glomerulosclerosis. Kidney Int 1993;43:1243–1250.
7.
Witztum JL: The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793–795.
8.
Steinberg D, Parthasarathy S, Carew TE, et al: Beyond cholesterol. N Engl J Med 1989;320:915–924.
9.
Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785–1792.
10.
Kita T, Nagano Y, Yokode M, et al: Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987;84:5928–5931.
11.
Salonen JT, Yla-Herttuala S, Yamamoto R, et al: Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883–887.
12.
Maggi E, Bellazzi R, Falaschi F, et al: Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45:876–883.
13.
Craig WY, Pouin SE, Nelson CP, et al: Elisa of IgG antibody to oxidized low-density lipoprotein: Effect of blocking buffer and method of data expression. Clin Chem 1994;40:882–888.
14.
Cazzolato G, Prakash G, Green S, et al: The determination of lipoprotein(a) by rate end-point nephelometry. Clin Chim Acta 1983;135:203–208.
15.
Monzani G, Bergesio F, Ciuti R, et al: Lp(a) levels: Effects of progressive chronic renal failure and dietary manipulation. J Nephrol 1997;10:41–45.
16.
Monzani G, Bergesio F, Ciuti R, et al: Lipoprotein abnormalities in chronic renal failure and dialysis patients. Blood Purif 1996;14:262–272.
17.
Attman PO, Alaupovich P: Lipid and apolipoprotein profile of uremic dyslipoproteinemia: Relation to renal function and dialysis. Nephron 1991;54:401–410.
18.
Maggi E, Bellazzi R, Gazo A, et al: Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994;46:869–876.
19.
Attman PO, Alaupovich P, Tavella M, et al: Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 1996;11:63–69.
20.
Yla-Herttuala S, Palinski W, Rosenfeld ME, et al: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086–1095.
21.
Wheeler DC, Chana RS, Topley N, et al: Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int 1994;45:1628–1636.
22.
Lee HS, Kim YS: Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int 1998;54:848–856.
23.
Klahr S: Oxygen radicals and renal diseases. Miner Electrolyte Metab 1997;23:140–143.
24.
Saha S: Oxidant mechanisms in glomerulonephritis. Semin Nephrol 1991;11:320–326.
25.
Muray A, Miyahara T, Fujimoto N, et al: Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986;59:199–204.
26.
Greiber S, Kreusel M, Pavenstadt H, et al: Lipoprotein(a) induces glomerular superoxide anion production. Nephrol Dial Transplant 1997;12:1330–1335.
27.
Loughrey CM, Young IS, Lightbody JH, et al: Oxidative stress in haemodialysis. Q J Med 1994;87:679–683.
28.
Dasgupta A, Hussain S, Ahmad S: Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron 1992;60:56–59.
29.
Roselaar SE, Nazhat NB, Winyard PG, et al: Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 1995;48:199–206.
30.
Giovannetti S: Supplemented diet for severe chronic renal failure: Some controversial points; in Oldrizzi L, Maschio G, Rugiu C, Campese VM (eds): The Progressive Nature of Renal Disease: Myths and Facts. Contrib Nephrol. Basel, Karger, 1989, vol 75, pp 147–154.
31.
Krajcovicova-Kudlackova N, Simoncic R, Babinska K, et al: Levels of lipid peroxidation and antioxidants in vegetarians. Eur J Epidemiol 1995;11:207–211.
32.
Pronczuk A, Kipervarg Y, Hayes KC: Vegetarians have higher plasma alpha-tocopherol relative to cholesterol than do nonvegetarians. J Am Coll Nutr 1992;11:50–55.
33.
Cominacini L, Garbin U, Pastorino AM, et al: Role of oxidized low density lipoprotein in the pathogenesis of atherosclerosis. Eur J Lab Med 1994;2:43–50.
34.
Rajman I, Harper L, McPache D, et al: Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 1998;13:2281–2287.
35.
Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785–1792.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.